{
    "ticker": "GALT",
    "name": "Galectin Therapeutics, Inc.",
    "description": "Galectin Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for fibrotic diseases and cancer. Founded in 2000, the company specializes in galectin biology, a unique field of research that targets galectins, which are a type of protein involved in various biological processes including cell growth, apoptosis, and immune response. Galectin Therapeutics is advancing its lead product candidate, GR-MD-02, a galectin-3 inhibitor, which is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis, conditions that have significant unmet medical needs. The company\u2019s research platform aims to develop treatments that can address fibrotic diseases across multiple organ systems as well as certain cancers. With a strong intellectual property portfolio and a commitment to scientific excellence, Galectin Therapeutics is poised to make significant contributions to the fields of hepatology, oncology, and immunology. The company's mission is to develop transformative therapies that improve patient outcomes and quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Norcross, Georgia, USA",
    "founded": "2000",
    "website": "https://www.galectintherapeutics.com",
    "ceo": "Peter G. Traber, M.D.",
    "social_media": {
        "twitter": "https://twitter.com/GalectinThera",
        "linkedin": "https://www.linkedin.com/company/galectin-therapeutics/"
    },
    "investor_relations": "https://www.galectintherapeutics.com/investor-relations/",
    "key_executives": [
        {
            "name": "Peter G. Traber, M.D.",
            "position": "CEO"
        },
        {
            "name": "R. Scott Jones",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "GR-MD-02"
            ]
        }
    ],
    "seo": {
        "meta_title": "Galectin Therapeutics, Inc. | Innovative Therapies for Fibrosis and Cancer",
        "meta_description": "Explore Galectin Therapeutics, Inc., a biotechnology company focused on developing innovative therapies for fibrotic diseases and cancer. Learn about their lead product candidate GR-MD-02 and their commitment to improving patient outcomes.",
        "keywords": [
            "Galectin Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "Fibrosis",
            "GR-MD-02",
            "NASH"
        ]
    },
    "faq": [
        {
            "question": "What is Galectin Therapeutics known for?",
            "answer": "Galectin Therapeutics is known for developing therapies for fibrotic diseases and cancer, particularly its lead product GR-MD-02."
        },
        {
            "question": "Who is the CEO of Galectin Therapeutics?",
            "answer": "Peter G. Traber, M.D. is the CEO of Galectin Therapeutics, Inc."
        },
        {
            "question": "Where is Galectin Therapeutics headquartered?",
            "answer": "Galectin Therapeutics is headquartered in Norcross, Georgia, USA."
        },
        {
            "question": "What is GR-MD-02?",
            "answer": "GR-MD-02 is the lead product candidate of Galectin Therapeutics, targeting galectin-3 for the treatment of NASH and advanced liver fibrosis."
        },
        {
            "question": "When was Galectin Therapeutics founded?",
            "answer": "Galectin Therapeutics was founded in 2000."
        }
    ],
    "competitors": [
        "GILD",
        "VRTX",
        "NVS",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "MSFT",
        "AMZN"
    ]
}